search
Back to results

Long-term Consumption of Resistant Starch Type-4 (RS4)

Primary Purpose

Cholesterol, Elevated, Overweight or Obesity

Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
RS4 bar
Control bar
Sponsored by
Kansas State University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Cholesterol, Elevated

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • BMI ≥ 23 kg/m2
  • elevated to borderline-high LDL-cholesterol (116-159 mg/dL)

Exclusion Criteria:

  • known allergy to wheat or gluten
  • currently taking medication for chronic disease including anti-inflammatory, anti-hypertensive, lipid lowering, glucose controlling, or steroidal medications
  • taking any supplements that may affect metabolism
  • having anemia or a history of anemia
  • current smoker or a user in the past three months
  • currently pregnant or lactating/planning to become pregnant during the intervention
  • having elevated blood pressure (≥130mmHg/≥80mmHg)
  • presence of diagnosed diabetes mellitus, inflammatory disease, atherosclerotic disease, or other relevant chronic conditions that may affect metabolic processes
  • total cholesterol ≥ 240mg/dL.

Sites / Locations

  • Physical Activity and Nutrition Clinical Research Consortium

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Resistant starch bar

Native wheat bar

Arm Description

The RS4 group will consume one nutrition bar per day formulated using Fibersym® RW.

The control group will consume one native wheat starch bar per day.

Outcomes

Primary Outcome Measures

Change in plasma lipids
Total cholesterol (TC), LDL-c , VLDL-c, HDL-c , triglycerides (TG) from blood sample in a fasted state

Secondary Outcome Measures

Change in body composition
Percent body fat as measured by DXA scan
Change in BMI
Weight and height will be combined to report BMI in kg/m^2
Change in homeostatic model assessment for insulin resistance (HOMA-IR)
Calculated from fasting glucose and insulin levels

Full Information

First Posted
February 18, 2020
Last Updated
October 2, 2023
Sponsor
Kansas State University
Collaborators
MGP Ingredients, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04277741
Brief Title
Long-term Consumption of Resistant Starch Type-4 (RS4)
Official Title
Long-term Consumption of Resistant Starch Type-4 (RS4): Implications for Obesity and Chronic Disease
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Withdrawn
Why Stopped
PI departure from university
Study Start Date
February 18, 2020 (Actual)
Primary Completion Date
June 30, 2023 (Anticipated)
Study Completion Date
June 30, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Kansas State University
Collaborators
MGP Ingredients, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary objective of the current proposal is to determine the effectiveness of long-term consumption of Fibersym® RW for improving blood lipids (including cholesterol) and body composition. The overall goal of this clinical research is to determine the potential effects that RS4 consumption may have on the prevention of obesity and obesity-related diseases. Fiber in the form of RS4 will be used for the proposed study, given that fiber has been shown to have many beneficial effects on modifiable risk factors associated with obesity-related diseases. Using a long-term randomized-controlled intervention design, blood lipids (total cholesterol, LDL-c, HDL-c, triglycerides) and body composition will be assessed. The investigators anticipate reductions in cholesterol and body fat percentage following 8-weeks of Fibersym® RW consumption.
Detailed Description
This study will investigate the metabolic effects of daily RS4 consumption in overweight and obese adults. The investigators will recruit approximately 50 (BMI: 23-34.9kg/m2) adults ages 18-65yrs, who have elevated to borderline-high LDL-cholesterol (116-159mg/dL) to an 8-week randomized controlled intervention. Participants will be recruited in three waves of 16 participants each. Following a 7-10-day run-in where fiber intake is monitored, participants will be randomized to either the control or the RS4 group. The RS4 group will consume a high fiber bar, daily, for 8-weeks that will contain approximately 60-70% of the daily reccomended allowance of fiber. The primary outcome for this study will be fasting plasma LDL-Cholesterol (LDL-c). Secondary outcomes include body composition following daily RS4 consumption for 8-weeks. All health assessments will be conducted before the intervention begins, at the 4-week mid-point, and immediately following the 8-week intervention. Participants will fast for 10 -12 hrs. before reporting to the PAN-CRC for each testing session. The meal consumed prior to each testing session will be standardized so that it does not vary within the individual between testing sessions. Treatments. The two treatment conditions are RS4 and control. Participants will be asked to consume one nutrition bar as part of their breakfast each day with no other changes to their diet. The control group will consume one native wheat starch bar per day. The RS4 group will consume one nutrition bar per day formulated using Fibersym® RW containing 20g fiber. This amount would likely put individuals in the recommended dietary fiber intake range according to the dietary recommended intake ( Institutes of Medicine: 14g fiber/1000 kcal). All nutrition bars will contain the same ingredients and be matched for calories; however, fiber will vary between the bars. Health assessments. The KSU Nutrition team will conduct all health assessments at each time point. Height (cm), weight (kg), and waist circumference (cm) will be measured to determine basic anthropometrics, and a dual-energy X-ray absorptiometry scan (DXA) will be used to determine body composition (body fat percentage and non-fat mass). Blood pressure (systolic and diastolic (mmHg) will be measured using a standard automated monitor. Fasting total cholesterol (TC), triglycerides (TRG), glucose, LDL-c, and HDL-c will be measured via an LDX Cholestech using a single venous blood draw for assessment. Plasma glucose and insulin will be determined via the same venous sample. Satiety will be measured during each testing session to determine how Fibersym® RW impacts feelings of fullness and hunger. Compliance Checks. To ensure compliance with consumption of the nutrition bars provided, participants will be asked to return to the PAN-CRC to return any leftover bars at the end of each intervention week (if any remain), and to pick up a new supply of their assigned bar. Participants will also be given a checklist that indicates their daily consumption of the given bars. The checklist will include options such as: I consumed the 100% of the bar, forgot to consume, consumed part of the bar (with options to check a percent of the bar consumed). To ensure that habitual dietary intake is maintained, participants will be instructed to complete a 3-day dietary record (two weekdays and 1 weekend day) prior to each testing session, allowing the investigators to determine any dietary changes that may occur during the 8-week intervention.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cholesterol, Elevated, Overweight or Obesity

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Masking Description
The participant will be blind to the condition that they are in.
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Resistant starch bar
Arm Type
Experimental
Arm Description
The RS4 group will consume one nutrition bar per day formulated using Fibersym® RW.
Arm Title
Native wheat bar
Arm Type
Active Comparator
Arm Description
The control group will consume one native wheat starch bar per day.
Intervention Type
Dietary Supplement
Intervention Name(s)
RS4 bar
Intervention Description
The RS4 group will consume one nutrition bar per day formulated using Fibersym® RW containing 20g fiber.
Intervention Type
Dietary Supplement
Intervention Name(s)
Control bar
Intervention Description
The control group will consume one native wheat starch bar per day.
Primary Outcome Measure Information:
Title
Change in plasma lipids
Description
Total cholesterol (TC), LDL-c , VLDL-c, HDL-c , triglycerides (TG) from blood sample in a fasted state
Time Frame
Week 0, 4, and 8
Secondary Outcome Measure Information:
Title
Change in body composition
Description
Percent body fat as measured by DXA scan
Time Frame
Week 0, 4, and 8
Title
Change in BMI
Description
Weight and height will be combined to report BMI in kg/m^2
Time Frame
Week 0, 4, and 8
Title
Change in homeostatic model assessment for insulin resistance (HOMA-IR)
Description
Calculated from fasting glucose and insulin levels
Time Frame
Week 0,4, and 8

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: BMI ≥ 23 kg/m2 elevated to borderline-high LDL-cholesterol (116-159 mg/dL) Exclusion Criteria: known allergy to wheat or gluten currently taking medication for chronic disease including anti-inflammatory, anti-hypertensive, lipid lowering, glucose controlling, or steroidal medications taking any supplements that may affect metabolism having anemia or a history of anemia current smoker or a user in the past three months currently pregnant or lactating/planning to become pregnant during the intervention having elevated blood pressure (≥130mmHg/≥80mmHg) presence of diagnosed diabetes mellitus, inflammatory disease, atherosclerotic disease, or other relevant chronic conditions that may affect metabolic processes total cholesterol ≥ 240mg/dL.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sara Rosenkranz, PhD
Organizational Affiliation
Kansas State University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Physical Activity and Nutrition Clinical Research Consortium
City
Manhattan
State/Province
Kansas
ZIP/Postal Code
66502
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Long-term Consumption of Resistant Starch Type-4 (RS4)

We'll reach out to this number within 24 hrs